70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups

Robbert C.A.M. Gielen, Coralie Poncet, Laura J. van ’t Veer, Isabel T. Rubio, Suzette Delaloge, Jean-Yves Pierga, Etienne Brain, Suzan Vrijaldenhoven, Peter A. Neijenhuis, Michail Ignatiadis, Giuseppe Viale, Fatima Cardoso, Martine Piccart, Emiel J.T. Rutgers, Marleen Kok, Caroline A. Drukker

Open source

DOI: 10.1016/j.ejca.2026.117044
Published: 2026-10
Container: European Journal of Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2026.117044,
  title = {70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups},
  author = {Robbert C.A.M. Gielen and Coralie Poncet and Laura J. van ’t Veer and Isabel T. Rubio and Suzette Delaloge and Jean-Yves Pierga and Etienne Brain and Suzan Vrijaldenhoven and Peter A. Neijenhuis and Michail Ignatiadis and Giuseppe Viale and Fatima Cardoso and Martine Piccart and Emiel J.T. Rutgers and Marleen Kok and Caroline A. Drukker},
  year = {2026},
  journal = {European Journal of Cancer},
  doi = {10.1016/j.ejca.2026.117044},
  url = {https://doi.org/10.1016/j.ejca.2026.117044}
}

RIS

TY  - JOUR
TI  - 70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups
AU  - Robbert C.A.M. Gielen
AU  - Coralie Poncet
AU  - Laura J. van ’t Veer
AU  - Isabel T. Rubio
AU  - Suzette Delaloge
AU  - Jean-Yves Pierga
AU  - Etienne Brain
AU  - Suzan Vrijaldenhoven
AU  - Peter A. Neijenhuis
AU  - Michail Ignatiadis
AU  - Giuseppe Viale
AU  - Fatima Cardoso
AU  - Martine Piccart
AU  - Emiel J.T. Rutgers
AU  - Marleen Kok
AU  - Caroline A. Drukker
PY  - 2026
JO  - European Journal of Cancer
DO  - 10.1016/j.ejca.2026.117044
UR  - https://doi.org/10.1016/j.ejca.2026.117044
ER  -

APA

Gielen, R. C., Poncet, C., Veer, L. J. V. ’., Rubio, I. T., Delaloge, S., Pierga, J., Brain, E., Vrijaldenhoven, S., Neijenhuis, P. A., Ignatiadis, M., Viale, G., Cardoso, F., Piccart, M., Rutgers, E. J., Kok, M., & Drukker, C. A. (2026). 70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117044

Source records

crossref · retrieved 2026-09-25T07:14:28.265Z